Skip to main content

Market Overview

Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration

Share:
Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration
  • A pair of large hospitals have declined to administer Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s treatment Aduhelm, Wall Street Journal reported.
  • The Cleveland Clinic and Mount Sinai Health System in New York said they wouldn’t administer the drug to patients amid a debate about the drug’s effectiveness and whether the FDA followed missteps in approving the treatment.
  • The Cleveland Clinic won’t carry the drug in its pharmacy or provide infusions. However, the doctors can still prescribe the medicine, and patients will have to receive their infusions at an outside facility.
  • Aduhelm is given a monthly infusion at an outpatient medical center.
  • Biogen priced the drug at $56,000 a year, though one health researcher said it would probably cost more for a typical patient.
  • A Biogen spokeswoman said that patients denied access to Aduhelm should contact Biogen for help.
  • Price Action: BIIB shares are down 6.90% at $327.76 during the market session on the last check Thursday.
 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Aduhelm BriefsBiotech News Short Ideas Health Care Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com